文献速递间质性肺疾病

血清S100A4在特发性肺纤维化中的临床意义

Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
PubMed 文献 · Respirology · 2019-10-09

本研究评估血清S100A4对特发性肺纤维化(IPF)预后的预测价值。95例连续IPF患者和50例健康对照的血清S100A4用ELISA检测,肺组织表达用免疫组化/免疫荧光分析,并采用Kaplan-Meier法和Cox回归评估与疾病进展和死亡的关系。结果显示IPF患者血清S100A4可检测出比例高于健康对照,且高水平与更差预后独立相关。

要点

  • IPF患者血清S100A4可检测率为27.3%,健康对照均未检出。
  • 血清S100A4高水平者2年累积生存率显著低于低水平者(41.7% vs 77.0%)。
  • 基线血清S100A4每升高10 ng/mL,疾病进展风险和死亡风险独立增加。

核心结论

  • 血清S100A4是有前景的生物标志物,可能有助于预测IPF疾病进展和死亡。

研究设计与样本

  • 研究纳入95例连续IPF患者和50例健康对照,检测血清S100A4水平及肺组织表达。

主要发现

  • 健康对照血清S100A4均不可检出,而95例IPF患者中26例(27.3%)可检出(P < 0.01)。
  • IPF患者肺组织中S100A4表达细胞聚集于成纤维细胞灶和成熟纤维化区域周围。
  • 血清S100A4较高者2年累积生存率为41.7%,较低者为77.0%(P < 0.01)。
  • 多因素分析中,基线血清S100A4每升高10 ng/mL,疾病进展风险比OR为1.06(P = 0.01),死亡风险比HR为1.18(P = 0.03)。

临床怎么用

  • 血清S100A4或可作为IPF患者疾病进展和死亡风险的辅助预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. There are no established serum biomarkers for predicting the outcomes of IPF. S100 calcium-binding protein A4 (S100A4) is considered as a marker of fibroblasts; however, its clinical application remains to be investigated. We evaluated the clinical relevance of S100A4 in IPF patients. METHODS: Serum S100A4 levels in 95 consecutive IPF patients and 50 healthy controls (HC) were measured using enzyme-linked immunosorbent assay. S100A4 expression in lung tissues was determined using immunohistochemistry/immunofluorescence and its association with disease progression (defined as deterioration in lung function or death) and mortality was assessed using Kaplan-Meier method and Cox hazards analysis. RESULTS: Serum S100A4 levels were undetectable in all HC but were detectable in 26 (27.3%) of the 95 IPF patients (P < 0.01). Immunostaining of lung tissues from IPF patients showed aggregation of numerous S100A4-expressing cells around the fibroblastic foci and mature fibrotic regions. IPF patients with higher serum S100A4 levels had a significantly worse prognosis than those with low serum levels (2-year cumulative survival rate: 41.7% vs 77.0%, respectively, P < 0.01). On multivariate analyses, baseline serum S100A4 levels (per 10 ng/mL increase) were independently associated with higher disease progression rate (odds ratio: 1.06, P = 0.01) and higher mortality (hazard ratio: 1.18, P = 0.03). CONCLUSION: S100A4 is a promising serum biomarker that may help predict disease progression/mortality. Our findings may help establish treatment strategies for IPF.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Akiyama N, Hozumi H, Isayama T, et al. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. Respirology. 2019. PMID: 31597225. doi:10.1111/resp.13707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。